Download presentation
Presentation is loading. Please wait.
Published byHélène Paré Modified over 5 years ago
1
The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation Stephen Couban, Peggy C. Wong, Kirk R. Schultz Experimental Hematology Volume 70, Pages 1-9 (February 2019) DOI: /j.exphem Copyright © 2018 Elsevier Ltd Terms and Conditions
2
Figure 1 Proposed effect of plerixafor mobilization on donor immune cell components. Based on murine and human data, plerixafor appears to increase release of immature NK cells, T cells, B cells, and dendritic cell populations. Some of these populations, including CD56bright NKreg cells and pre-pDCs, appear to be have regulatory immune function and decreased cGvHD (CD56bright NKreg cells) and aGvHD (CD56bright NKreg cells and pre-pDCs). Experimental Hematology , 1-9DOI: ( /j.exphem ) Copyright © 2018 Elsevier Ltd Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.